Online inquiry

IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15394MR)

This product GTTS-WQ15394MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ15394MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8163MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HL036337
GTTS-WQ9071MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMC-A12
GTTS-WQ11872MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MLN-0264
GTTS-WQ1702MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ8399MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HS006
GTTS-WQ14790MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SGN-40
GTTS-WQ10291MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LGT209
GTTS-WQ1035MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-399
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW